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EDITORIAL
Coronary Artery Spasm and Flow-Limiting 
Coronary Stenoses: A Malevolent Duo?
Juan Carlos Kaski , DSc, MD
Flow-limiting coronary atherosclerotic obstructions can cause myocardial ischemia and severe an-gina, which impair both quality of life and clinical 
outcomes. On the other hand, coronary artery spasm, 
a functional disorder of the coronary artery, as seen 
typically in Prinzmetal variant angina, can cause tran-
sient coronary blood flow reductions, severe angina 
pectoris, life-threatening arrhythmias, and myocar-
dial infarction (MI), in the presence or in the absence 
of obstructive coronary artery disease (CAD).1 The 
identification of flow-limiting atherosclerotic epicardial 
coronary obstructions with the use of coronary physi-
ological investigations (ie, fractional flow reserve [FFR]) 
has markedly influenced our approach to the manage-
ment of obstructive CAD over the past years.2 It has 
also generated a belief among patients and healthcare 
professionals alike that in addition to improving myo-
cardial ischemia and anginal symptoms, the elimina-
tion of the flow-limiting effect of a coronary stenosis 
by coronary revascularization with surgical bypass 
or percutaneous coronary intervention also reduces 
the incidence of MI and improves patient clinical out-
comes. Although the latter is right in high-risk patients 
with acute coronary syndrome and ST-segment–el-
evation MI, the concept is not necessarily fully ap-
plicable to patients with chronic coronary syndrome 
(stable angina), as shown by several meta-analyses 
and large randomized studies,3–6 including the recent 
ISCHEMIA (International Study of Comparative Health 
Effectiveness With Medical and Invasive Approaches).6 
Indeed, in ISCHEMIA,6 the primary study end point did 
not differ significantly in patients with chronic coronary 
syndrome who were undergoing revascularization 
compared with conservatively treated patients with 
chronic coronary syndrome (16.4% and 18.2%, re-
spectively; 95% CI, 4.7–1.0). For the major secondary 
end point of cardiovascular mortality or MI, the hazard 
ratio (HR) for the invasive versus conservative strate-
gies was 0.90 (95% CI, 0.77–1.06; P=0.21). More im-
portant, there were no between-group differences in 
either all-cause mortality (5.6% in each arm; HR, 1.05 
[95% CI, 0.83–1.32]; P=0.67) or cardiovascular mortal-
ity (HR, 0.87 [95% CI, 0.66–1.15]; P=0.33) during fol-
low-up. Although ISCHEMIA6 highlighted the important 
role of optimal medical therapy in patients with stable 
angina who had obstructive CAD, the study excluded 
patients whose anginal symptoms occurred in the 
absence of obstructive coronary artery stenosis and 
did not look into the role of invasive versus medical 
treatment of functional causes of angina (ie, coronary 
artery spasm). Functional mechanisms of myocardial 
ischemia, including epicardial coronary artery spasm 
and coronary microvascular dysfunction, play an im-
portant pathogenic role in both patients with and pa-
tients without obstructive CAD, but cardiologists have 
not embraced this notion universally.7 More important, 
coronary artery spasm can lead to refractory angina 
and both acute MI and life-threatening arrhythmias,1 
and in recent years, studies have shown that the pres-
ence of coronary microvascular dysfunction is associ-
ated with impaired cardiovascular outcomes in patients 
with or without obstructive CAD.8 It is therefore con-
ceivable that not only organic coronary stenoses but 
different combinations of obstructive and functional 
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mechanisms, often coexisting in the individual patient, 
are finally responsible for the many different forms of 
presentation of ischemic heart disease in clinical prac-
tice, and the often unpredictable clinical evolution of 
the disease process, in certain patients.
Interestingly, although cardiologists are aware of 
the important role of functional mechanisms in the 
pathogenesis of angina pectoris, anatomical assess-
ment of the epicardial coronary arteries with conven-
tional coronary angiography continues to be used as 
the gold standard diagnostic test for angina, despite 
the limitations of the technique to determine the hemo-
dynamic effects of a coronary stenosis or to evaluate 
vasomotor changes that may occur in the epicardial 
arteries or in the coronary microvasculature and can, 
per se, trigger angina in patients with or without ob-
structive CAD. Unfortunately, this diagnostic strategy, 
used in routine clinical practice for several decades 
now, has precluded a proper understanding of the in-
cidence and relevance of coronary vasomotion abnor-
malities as a cause of myocardial ischemia or the true 
prognostic role of combined obstructive CAD and su-
perimposed coronary spasm in patients with angina. 
However, the implementation of coronary physiological 
tests to establish the flow-limiting effects of epicardial 
coronary stenoses2 and, more recently, of tests of cor-
onary microvascular function9 is helping physicians 
to understand how complex a problem angina/isch-
emic heart disease truly is. Interestingly, despite the 
established role that coronary artery spasm plays in 
the pathogenesis of different coronary syndromes, 
tests for coronary spasm are not routinely performed 
in patients with obstructive CAD. In this issue of the 
Journal of the American Heart Association (JAHA), an 
article by Hao et al10 contributes to our understanding 
of the prognostic role of the combined assessment of 
flow-limiting obstructive CAD and epicardial coronary 
artery spasm. They observed that patients with both 
coronary artery spasm and flow-limiting atheromatous 
coronary stenoses (ie, FFR <0.80) represent a high-
risk subgroup. Briefly, the study involved 236 consec-
utive patients with angina who underwent coronary 
arteriography and both acetylcholine provocation for 
coronary spasm and FFR measurements to establish 
the flow-limiting effect of obstructive coronary steno-
ses, with 175 patients having a positive test result for 
coronary spasm. Of these patients, 110 had no or-
ganic stenosis (<50% lumen diameter reduction), 36 
had obstructive CAD but no flow-limiting stenoses 
(FFR >0.80), and 29 had significant stenoses and a re-
duced FFR <0.80. All patients with vasospastic angina 
received treatment with calcium channel blockers, and 
28 of the 29 (95%) patients with reduced FFR also un-
derwent elective percutaneous coronary intervention. 
During a median follow-up of almost 2 years, the in-
cidence of major adverse cardiac events was low 
and similar among patients with vasospastic angina 
and no obstructive CAD and patients with obstruc-
tive CAD but no flow-limiting stenoses. Conversely, 
patients with both coronary spasm and CAD with low 
FFR had markedly impaired clinical outcomes, despite 
appropriate treatment with calcium channel blockers 
and percutaneous coronary intervention. The reasons 
for the markedly impaired clinical outcomes in these 
patients were not explored in the study, but the au-
thors speculate that ρ-kinase activation may play a role 
and that the administration of angiotensin-converting 
enzyme inhibitors may have beneficial effects in ad-
dition to those of calcium channel blockers, conceiv-
ably through enhanced bradykinin concentration and 
inhibition of the ρ-kinase pathway.11,12 The findings by 
Hao et al10 are of potential clinical importance as they, 
first, highlight the safety and usefulness of performing 
provocative tests for coronary spasm, even in patients 
with obstructive CAD, and, second, showed what ap-
pears to be a synergistic effect of obstructive CAD and 
coronary spasm, leading to markedly impaired clinical 
outcomes in patients with coronary spasm and CAD 
with low FFR that is not beneficially affected by stenting 
and/or the use of calcium channel blockers. Another 
important finding in the study was that provocative 
testing for coronary spasm was safe, as previously re-
ported by other investigators.13–15
Despite the potentially major clinical implications 
of the findings by Hao et al,10 their work is not with-
out limitations. Indeed, the study is nonrandomized 
and retrospective in nature, and it involved a relatively 
small number of patients who were assigned to differ-
ent clinical subgroups, thus reducing the power of the 
study further. Moreover, patients with coronary spasm 
patients who had obstructive CAD had a higher prev-
alence of major risk factors (ie, diabetes mellitus and 
dyslipidemia), which could have affected clinical out-
comes. Another limitation, also identified by the au-
thors, is that in this single-center study, the decision 
to proceed to acetylcholine provocation testing and 
selecting the treatment strategy were left to the dis-
cretion of the treating cardiologists, potentially result-
ing in selection bias. Despite these limitations, which 
have to be considered carefully when trying to establish 
the clinical relevance of the reported findings and the 
need for further research to be performed to confirm 
or disprove the findings of Hao et al, their study has 
merit. Their findings not only are hypothesis generating 
but offer at least a preliminary answer to the frequently 
asked clinical question as to whether patients with re-
current coronary artery spasm, with or without CAD, 
may benefit from percutaneous coronary intervention/
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stenting at the spastic site. The study clearly suggests 
that revascularization does not have the desired ther-
apeutic effect and may be even harmful in these pa-
tients. Clinicians now eagerly await the results of large, 
randomized, placebo-controlled studies that can help 
to both provide further insight into the mechanisms 
leading to serious cardiovascular events when coro-
nary spasm and obstructive stenoses coexist in a given 
patient and help identify effective treatments for pa-
tients with angina caused by the combined actions of 
flow-limiting obstructive CAD and vasospastic angina.
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Table S1. Comparison of clinical characteristics of LVNC patients with and without LA 
dilatation (left atrial volume index >34 ml/m2). 






Age (years) 56 (44-65) 39 (28-51) <0.001 
Female sex  64 (40%) 84 (79%) 0.025 
Hypertension  64 (40%) 34 (21%)  <0.001 
Diabetes mellitus 23 (14%) 16 (10%) 0.23 
Smoking 55 (34%) 44 (28%) 0.18 
Stroke/TIA 13 (8%) 4 (3%) 0.02 
Coronary artery disease 35 (22%) 11 (7%) <0.001 
Congestive heart failure 63 (39%) 31 (19%) <0.001 
Left Ventricular Ejection fraction (%) 36 (23-51) 53 (40-60) <0.001 
Left ventricular ejection fraction <50% 114 (71%) 68 (43%) <0.001 
Atrial fibrillation/flutter 55 (34%) 18 (11%) <0.001 
Any cardiovascular implantable device 29 (18%) 25 (16%) 0.55 
Asymptomatic at presentation 33 (21%) 52 (33%) 0.017 
Echocardiographic variables    
  Left ventricular end diastolic diameter 59 (53-65) 51 (48-57) <0.001 
  Left ventricular end systolic diameter  48 (38-56) 36 (32-43) <0.001 
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Any RV enlargement 54 (34%) 27 (17%) <0.001 
Any RV dysfunction 58 (37%) 28 (18%) <0.001 
Moderate or greater mitral regurgitation 34 (22%) 7 (5%) <0.001 
Increased LV wall thickness (LV mass index 
>95 gm/m2: women; >115 gm/m2: men)  
105 (66%) 53 (33%) <0.001 
Minimum systolic compacta thickness (mm) 6 (5-7) 6 (5-6) 0.015 
Maximum systolic noncompacta thickness 
(mm) 
19 (17-22) 17 (14-20) <0.001 
  Maximum end systolic NC:C ratio (Jenni 
criteria) 
2.8 (2.5-3.4) 2.8 (2.4-3.2) 0.45 
  Minimum end diastolic X:Y ratio (Chin 
criteria, per 0.1 unit increase in the ratio) 
0.26 (0.22-0.29) 0.26 (0.22-0.30) 0.27 
  Number of segments involved 2 (1-3) 1 (1-3) 0.03 
Isolated apical noncompaction 71 (44%) 84 (53%) 0.14 
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Supplemental Video Legends: 
 
Video S1. Left ventricular noncompaction patient with mid-basal noncompaction extent. 
NC:C and X:Y ratios met for segments extending beyond the apical segment. Best viewed with 
Windows Media Player. 
 
Video S2. Left ventricular noncompaction patient with isolated apical noncompaction 
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